



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/044001
	Serial No.	10/031,313
	Applicant	Hallek et al.
	Filing Date	June 3, 2002
	Group	1648
	IDS Filed	January 18, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
/SBC/	2001/031463	10/18/01	Kleinschmidt et al. 2001/0031463
/SBC/	2002/0192823	12/19/02	Bartlett et al.
/SBC/	5,276,136	01/04/94	Skubitz et al.
/SBC/	6,491,907	12/10/02	Rabinowitz et al.

KS
04/19/07

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/SBC/	Anderson, "Human Gene Therapy," <i>Nature</i> 392:25-30 (1998).
	Asokan et al., "AAV Does the Shuffle," <i>Nature Biotechnology</i> 24:158-160 (2006).
	Buning et al., "Receptor Targeting of Adeno-Associated Virus Vectors," <i>Gene Therapy</i> 10:1142-1151 (2003).
	Grifman et al., "Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-Associated Virus Capsids," <i>Molecular Therapy</i> 3:964-975 (2001).
	Hoque et al., "Nuclear Transport of the Major Capsid Protein is Essential for Adeno-Associated Virus Capsid Formation," <i>Journal of Virology</i> 73:7912-7915 (1999).
	Huttner et al., "Genetic Modifications of the Adeno-Associated Virus Type 2 Capsid Reduce the Affinity and the Neutralizing Effects of Human Serum Antibodies," <i>Gene Therapy</i> 10:2139-2147 (2003).
↓	Kmiec, "Gene Therapy," <i>American Scientist</i> 87:240-247 (1999).

EXAMINER /Stacy B. Chen/	DATE CONSIDERED 03/26/2007
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	